ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

UNCY vs OKUR // RETURN ON INVESTED CAPITAL (ROIC)

Unicycive Therapeutics Inc. (NASDAQ) VS. OnKure Therapeutics Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: UNCY 0 — OKUR 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UNCY VS. OKUR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC UNCY OKUR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.5 50.9 -10.40 OKUR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $104.2M $106.1M -$1.9M OKUR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR UNCY REV OKUR REV UNCY GROSS % OKUR GROSS % UNCY FCF OKUR FCF
FY 2025 $82.6M $176.3M — — -$31.3M -$51.9M
FY 2024 $89.9M $152.3M — — -$28.6M -$51.2M
FY 2023 $675.0K $103.4M — — -$18.3M -$34.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UNCY // BETA —
OKUR // BETA —